Big Pharma and Orphan Drugs: The Case for Thinking Small
This article was originally published in RPM Report
Executive Summary
In this issue, The RPM Report looks at three advocates making three different but inter-related cases for greater involvement by Biopharma companies in research into rare diseases. Do they have any takers?
You may also be interested in...
FDA Looking To Patient Advocates To Answer Benefit-Risk Questions
FDA’s clinical review teams are starting to approve novel drugs and biologics using a new structured benefit-risk framework developed under PDUFA V. Those assessments ask reviewers to think more broadly about the disease and how a new treatment might fit into the current treatment model. But many reviewers don’t have that information. And that, FDA says, is where patient advocates come in.
Valuing Genzyme: A Health Care Reform Premium
Sanofi has gone public with an $18.5 billion bid for Genzyme, but investors assume the French company is willing to go higher. So the question everyone is asking is, How much is Genzyme worth? The answer should include a premium for the special treatment the company will get under the health care reform law in the US.
Valuing Genzyme: A Health Care Reform Premium
Sanofi has gone public with an $18.5 billion bid for Genzyme, but investors assume the French company is willing to go higher. So the question everyone is asking is, How much is Genzyme worth? The answer should include a premium for the special treatment the company will get under the health care reform law in the US.